Report cover image

Hospital Acquired Pneumonia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Publisher GlobalData
Published Sep 06, 2022
Length 76 Pages
SKU # GBDT17417943

Description

Hospital Acquired Pneumonia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Hospital Acquired Pneumonia therapeutics.

Synopsis
  • In 2022, there will be more than 300,000 diagnosed incidence cases of HAP across seven major pharmaceutical markets.
  • There are six leading marketed drugs for the treatment of HAP, and Merck is a key player in the disease space.
  • Out of 47 drugs in HAP pipeline, , five drugs are in Phase III and three drugs are in pre-registration development stage.
  • Non-industrial sponsors dominate clinical trial development in HAP, with China and Russia emerging as the key countries for conducting trials in HAP.
  • During the past 12 months, there have been six mergers and acquisitions, and five strategic alliances involving HAP assets.
  • Approval of Shionogi’s cefiderocol in Japan is anticipated in March 2023 for the treatment of HAP.
Scope

GlobalData’s Hospital Acquired Pneumonia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Retail or Manufacturer Price of Products
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Hospital Acquired Pneumonia market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Hospital Acquired Pneumonia market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

76 Pages
  • Key Findings
  • Disease Overview
    • Epidemiology Overview: Total Prevalent Cases of HAP in 2022
    • Treatment Guidelines
    • Marketed Drugs - Leading Marketed Drugs in HAP
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drug Profile: Pfizer's Avycaz/Zavicefta
    • Marketed Drug Profile: Merck's Zerbaxa
    • Marketed Drug Profile: Merck's Recarbrio
    • Marketed Drug Profile: Melinta Therapeutics/Menarini group's Vabomere/Vaborem
    • Marketed Drug Profile: Shionogi's Fetcroja/Fetroja
    • Marketed Drugs - Manufacturer Price (in USD/mg)
    • Marketed Drugs - Time to Pricing and Reimbursement for Avycaz/Zavicefta
    • Marketed Drugs - Time to Pricing and Reimbursement for Zerbaxa
    • Marketed Drugs - Time to Pricing and Reimbursement for Recarbrio
    • Marketed Drugs - Time to Pricing and Reimbursement for Vabomere/Vaborem
    • Marketed Drugs - Time to Pricing and Reimbursement for Fetroja/Fetcroja
    • Pipeline Drugs Overview - Phase II and above Pipeline Drugs in HAP
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Drug-Specific PTSRs and LoA in HAP
    • Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Infectious disease and in HAP
    • Clinical Trials in HAP - Historical Overview
    • Clinical Trials in HAP - Overview by Phase
    • Clinical Trials in HAP - Overview by Status
    • Clinical Trials in HAP - Overview by Phase for Ongoing and Planned Trial
    • Clinical Trials in HAP - Trials with a Virtual Component
    • Clinical Trials in HAP - Geographic Overview
    • Clinical Trials in HAP - Single-Country and Multinational Trials by Region
    • Clinical Trials in HAP - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in HAP - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in HAP - Overview by Endpoint Status
    • Clinical Trials in HAP - Overview by Race and Ethnicity
    • Clinical Trials in HAP - Enrollment Data
    • Clinical Trials in HAP - Overview of Sites by Geography
    • Clinical Trials in HAP - Top 20 Countries for Trial Sites
    • Clinical Trials in HAP - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for HAP
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in HAP by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in HAP
    • Commercial Assessment - Key Market Players in HAP
    • Future Market Catalysts - Upcoming Market Catalysts in HAP
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
  • Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us